Neovasc Inc (NASDAQ: NVCN) is having an overwhelmingly strong start to the trding session this morning after the company announced that its Tiara and Reducer products will be featured in coming presentations. The news comes just after the company announced the 100th successful Reducer implant in Germany. Of course, the news excited investors, sending the stock on a run for the top. Today, we’ll talk about:
- The coming presentations;
- what we’re seeing from NVCN stock as a result; and
- what we’ll be watching for ahead.
NVCN Heads Up On Coming Presentations
As mentioned bove, Neovasc is having an incredibly strong start to the trading session this morning after the comapny announced that its products will be featured in coming presentations. In a press release issued early this morning, NVCN said that its Riara, transcatheter treatment of mitral valve disease and Reducer, a device used to treat refractory angina, will both be fatured in several presentations at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium. The event will take place between September 21 and September 25 in San Diego, CA.
In a statement, Fred Colen, President and CEO at NVCN, had the following to offer:
We are pleased to announce that the Neovasc team will be engaged in many scientific discussions with top Cardiologists from around the world to discuss and advance our two key product platforms, the Tiara and the Reducer, at the 2018 TCT conference, which is the largest interventional cardiology conference in the world. There will also be two presentations, specifically regarding our products. This is the most important educational meeting specializing in interventional cardiovascular medicine every year.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of Neovasc, the news proved to be overwhelmingly positive. With the coming presentations the company will be in front of several investors and could drive key funding. So, it comes as no surprise that excited investors are sending the stock screaming for the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:45), NVCN is trading at $0.031 per share after a gain of $0.0041 per share or 15.24% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NVCN. In particular, we’re interested in following the continued work to bring the Tiara and the Reducer to patients in need around the world. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!